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Abstract
Background Scabies has been estimated to affect approximately 300 million people
worldwide each year. Scabies rates are high and pose a significant public health problem
in Fiji. Community-based comparison treatment trials have not been undertaken. We
estimated scabies prevalence and compared the efficacy and tolerability of mass drug
administration (MDA) of benzyl benzoate lotion (BB) or oral ivermectin (IVM) in two villages
in Fiji.
Methods A prospective MDA trial was undertaken in two Fijian villages, comparing three
daily applications of BB with single dose IVM or permethrin cream for those aged under
two years. The therapies were offered to all community members regardless of the
presence of scabies or its symptoms. The difference in prevalence was measured before
and after the intervention and absolute risk reduction (ARR) and relative risk (RR)
calculated.
Results In the BB group, there were 572 eligible participants, of whom 435 (76%) enrolled
and 201 (46%) returned for follow-up. In the IVM group, there were 667 eligible
participants, of whom 325 (49%) enrolled and 126 (39%) returned. Scabies prevalence
was lower after the intervention in both groups. It fell from 37.9 to 20.0% (ARR 18.0%; RR
0.52) in the BB group and from 23.7 to 9.5% (ARR 14.2%; RR 0.40) in the IVM group.
Conclusions Our study provides proof of principle that MDA for scabies can reduce
scabies prevalence at the community level, and that there was no significant difference in
this trial between BB and oral IVM.
Introduction
Scabies, due to infestation with the Sarcoptes scabiei mite,
has been estimated to affect approximately 300 million
people worldwide each year. Its direct impact is itching,
but secondary bacterial infection with Streptococci and
Staphylococci is frequent and can lead to serious and
potentially fatal complications, including invasive bacte-
rial infections, renal failure, and chronic rheumatic heart
disease.1–4.
The highest rates of scabies in the world are found in
Pacific island countries.5 In a population-based survey in
Fiji, 24% of participants had scabies, with a particularly
high prevalence in young children (L. Romani, personal
communication). A prospective study in Fijian schoolchil-
dren documented scabies incidence at 51 cases per 100
person-years.6
Scabies treatment is primarily with application of topi-
cal agents, including benzyl benzoate and permethrin
cream, which was introduced to Fiji in 2006 and is now
the standard of care.7 As S. scabiei is transmitted by close
body contact or shared objects, treatment of close con-
tacts is also recommended. One oral agent, ivermectin
(IVM), has been used as single dose scabies treatment,
repeated at two weeks if symptoms persist.8–10
The frequency of reinfestation in endemic settings has
led to consideration of mass drug administration (MDA)
as a public health option for scabies control. Small,
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uncontrolled studies in closed communities such as prisons
and aged care facilities have suggested that treatment of
entire communities can sharply reduce the prevalence of
infestation,8,11–13 using either topical treatment or oral
IVM, the latter perhaps offering better adherence and
fewer side effects.14 To assess the potential role of MDA
in an open community setting in the general population,
we studied oral vs. topical MDA in two Fijian villages.
Materials and methods
We performed a prospective trial comparing the efficacy and
tolerability of two MDA treatment regimens for the control of
scabies by offering treatment to all community members
regardless of the presence of scabies or its symptoms. Hence,
all family members of study participants, including
asymptomatic family members of patients with scabies living in
either village, were offered treatment immediately after
examination and included in the study.
We conducted the study in two Fijian subdivisions (local
administrative areas) in June and July 2004. The sites were
selected by the Fiji Ministry of Health as having
approximately the same number of inhabitants and being
within a 2-hour drive of the capital, Suva, but relatively
isolated from each other and from other communities.
Allocation to treatment was decided by administrative chance
based on the availability of medication at start point. In the
Tailevu subdivision, three closely linked settlements
(Sawakasa, Dakuinuku, and Lodoni, total population 572)
were classified as one site. In the Rewa subdivision,
Raralevu village was selected (total population 667). All Fijian
nationals living in either of the two sites were considered
eligible for the study and were enrolled after signing the
consent forms, with parents signing for their children. Study
participants were registered by name, age, and sex and were
weighed at initial visit. After enrollment, participants were
identified only by their numeric code and no further identifying
data were used in the study.
Participants were asked to complete questionnaires at
enrollment and follow-up visit, in either English or Fijian, and
assisted by the local community nurse if necessary. Each
participant was examined by a healthcare professional with
experience in scabies diagnosis and treatment and reviewed by
a senior doctor if any skin lesions were seen. The diagnosis of
scabies was made clinically, based on the presence of
characteristic lesions with or without a history of itch. Suspected
scabies lesions, either papules, pustules, or crusted lesions on
the trunk and limbs, were counted and other dermatological
conditions, such as boils and sores, eczema, and tinea were
documented before and after treatment. If appropriate, oral
antibiotics were given for secondarily infected lesions and
therapy provided for other skin conditions. The extent of
scabies was quantified as mild (10 lesions or fewer), moderate
(11–49), severe (50 or more), or crusted (confluent lesions, too
many to count).15–17 The diagnosis of infected lesions was
made based on the presence of erythema, crusting, or
pustules.
Interventions
All MDA study participants in the Rewa subdivision site (IVM
group) aged 2 years and over with no medical contraindications
received a single dose of oral IVM at 200 lg/kg body weight
(Stromectol 3 mg tablets; Merck Sharp & Dohme, South
Granville, NSW, Australia), rounded to whole 3 mg IVM tablets.
IVM was taken orally under direct observation, immediately
after examination. Children aged <2 years received topical 5%
permethrin cream (Lyderm; Makans Drug & Pharmaceutical
Supplies, Taravao, Fiji) to be applied from neck to toes.
Pregnant (n = 2) and lactating women, and people who
reported a history of neurological disease, such as stroke
(n = 2) or neurofibromatosis (n = 1), were also given 5%
permethrin cream.
At the time of the study, benzyl benzoate was the standard
treatment for scabies in Fiji, available free through clinics, and
both benzyl benzoate and permethrin were available for
purchase from the private pharmacies. According to the national
protocol, participants in the Tailevu subdivision site (benzyl
benzoate, BB group) were given 25% topical benzyl benzoate
lotion, diluted to 12.5% for children aged 2–12 years, and 8.3%
for those aged less than 2 years. Adults were each provided
with one 100 ml bottle of benzyl benzoate 25% and asked to
apply it that night, and on two successive nights, from neck to
toes, covering all areas. Participants were asked to leave it on
for 24 hours, then wash and re-apply, following the
recommended guidelines for benzyl benzoate in Fiji at that time.
Participants in both sites were provided with information
about the medication they were offered and advised of the need
to wash themselves, their bed linen, and clothes used within the
previous 24 hours.
Follow-up assessment
In the BB group, the follow-up assessment took place 28 days
after the initial visit, whereas in the IVM group it was at
24 days. At the follow-up visit, participants were re-examined;
scabies lesions were counted and recent medical history
recorded. If required, patients were given treatment for any
persistent skin lesions.
All participants were specifically asked if they had
experienced any adverse events apart from itch following
treatment and if they had sought medical care for these events.
In the self-administered post-treatment questionnaire,
information was additionally collected on itch after treatment.
Statistical analysis
Data were entered into an SPSS database version 11.5 for
Windows. Statistical analysis was conducted using STATA 12
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(StataCorp LP, College Station, TX, USA) and IBM SPSS
statistics Version 19 (IBM Company, Armonk, NY, USA).
Differences in distributions of categorical variables were tested
using a chi-squared test. Student’s two-sample t-test was used
to compare means. The effects of the interventions were
measured by comparing the prevalence of scabies at follow-up
with that before intervention by comparing the reduction of
absolute risk with calculation of 95% confidence intervals (CI)
and relative risk with 95% CIs between the two periods. For
comparison of other skin diseases pre- and post-intervention,
McNemar’s test was used. Non-overlapping CIs were
considered to be at the significance level.
Ethical approval
Ethics approval for the study was obtained from the Fiji National
Research Ethics Review Committee and reviewed by St.
Vincent’s Hospital Ethics Committee in Sydney.
Results
Participation and follow-up rates
A higher proportion of the population was enrolled in the
BB group than the IVM group (76% vs. 49% respec-
tively, Fig. 1). Otherwise, participant demographics at the
two sites did not differ significantly in regards to sex, age,
or weight at baseline (Table 1). Of the 435 enrolled in
the BB group, 201 (46%) returned for follow-up. In the
IVM group, 325 were enrolled and 126 (39%) returned
for follow-up.
Specifically there was significantly higher follow-up in
children under the age of five years in the BB group
(45.5%) than in the IVM group (20.0%) (P = 0.01; OR
3.3; 95% CI 1.4–8.2), in contrast to those aged
5–14 years, where 54.2 and 70.3% attended follow-up
(P = 0.01; OR 0.5; 95% CI 0.3–0.8). In people aged
15–29 years, the difference was highest, 29.6% attending
for follow-up in the BB and 9.4% in the IVM group
(P = 0.01; OR 4.0; 95% CI 1.4–11.4).
At the baseline visit, differences were noted between
the two groups, in particular scabies prevalence was
higher in the BB group (37.9%) compared to the IVM
group (23.7%) (Table 2). Infected scabies was also more
common in the BB group. Overall, the severity of scabies
at baseline, defined by the number of lesions, did not sig-
nificantly differ between the two villages. Many study
participants had other skin conditions at baseline, overall
more common in the IVM group (36.6%) compared to
the BB group (26.7%).
Scabies prevalence after mass drug administration
Comparing the prevalence of scabies before and after
MDA, the reduction in prevalence was significant in both
groups but similar in magnitude (Table 3). After MDA,
scabies lesions were present in 40 of 201 people examined
(20.0%) in the BB group and 12 of 126 examined (9.5%)
in the IVM group. The absolute risk reduction in the BB
group was 18% (95% CI 10.5–24.8) with a relative risk
of 0.52 (95% CI 0.39–0.71), whereas in the IVM group
the absolute risk reduction was 14.2% (95% CI 6.5–
20.5) with a relative risk of 0.40 (95% CI 0.23–0.71).
Similar reduction in prevalence was observed consistently
across all age groups.









All participants 760 (100.0) 435 (57.2) 325 (42.8) –
Sex
Male 353 (46.4) 194 (44.6) 159 (48.9) 0.257
Female 407 (53.6) 241 (55.4) 166 (51.1)
Ethnicity
Fijian 524 (98.5) 278 (97.5) 246 (99.6) 0.053b
Othersa 8 (1.5) 7 (2.5) 1 (<1)
Median age (IQR) 16 (8–43) 16 (8–41) 16 (8–44) 0.795c
<5 years 100 (13.2) 55 (12.6) 45 (13.8) 0.785b
5–14 years 264 (34.7) 153 (35.2) 111 (34.2)
15–29 years 134 (17.6) 81 (18.6) 53 (16.3)
30+ years 262 (34.5) 146 (33.6) 116 (35.7)
BB, benzyl benzoate group; IVM, ivermectin group.
aIncludes six Indian–Fijian (all in Tailevu) and two European
(one in Tailevu and one in Rewa).
bChi-squared test.
cWilcoxon rank-sum test.
Figure 1 Flow chart of participation and follow-up rate at
each study site
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Other skin conditions were noted in 32.3% (65 of 201)
of participants in the BB group and in 42.1% (53 of 126)
in the IVM group after treatment. There was no signifi-
cant difference in the change in prevalence of other skin
conditions at baseline and follow-up in either group over-
all; however, diagnoses of boils and sores increased in the
BB group from 1.0 to 5.0% (P = 0.04) and fungal dis-
eases in the IVM group from 15.1 to 24.6% (P = 0.02)
in participants who attended both visits.
Tolerability and acceptability of treatments
Nineteen of 200 people (9.5%) reported having had
adverse events (apart from itch exacerbation) after
treatment in the BB group whereas only three of 126
(2.4%) did in the IVM group (P = 0.01, OR 4.3, 95% CI
1.25–14.86). The reported side effects included stinging
and burning in the BB group and lethargy and giddiness
in the IVM group. No study participants presented for














Scabies 242 (31.8) 165 (37.9) 77 (23.7) 52 (15.9) 40 (19.9) 12 (9.5)
Number of lesions
≤10 111 (45.9) 65 (39.4) 46 (59.7) 25 (48.1) 18 (45.0) 7 (58.3)
11–49 74 (30.6) 50 (30.3) 24 (31.2) 21 (40.4) 16 (40.0) 5 (41.7)
≥50 16 (6.6) 9 (5.5) 7 (9.1) 4 (7.7) 4 (10.0) 0 (0.0)
Crusteda 4 (1.6) 4 (2.4) 0 (0.0) 2 (3.8) 2 (5.0) 0 (0.0)
Number not recorded 37 (15.3) 37 (22.4) 0 (0.0) – – –
Infected scabies 85 (11.2) 68 (15.6) 17 (5.2) 10 (3.1) 8 (4.0) 2 (1.6)
Boils/abscess 27 (3.6) 7 (1.6) 20 (6.2) 18 (5.5) 10 (5.0) 8 (6.4)
Eczema/dermatitis 46 (6.1) 23 (5.3) 23 (7.1) 19 (5.8) 10 (5.0) 9 (7.1)
Tinea 144 (19.0) 71 (16.3) 73 (22.5) 72 (22.0) 41 (20.4) 31 (24.6)
Other skin disease 25 (3.2) 20 (4.6) 5 (1.5) 14 (4.3) 7 (3.5) 7 (5.6)
BB, benzyl benzoate group; IVM, ivermectin group.
aConfluence of lesions precluded accurate counting.




























38/55 (69.1) 9/25 (36.0) 33.1 (10.0–52.1) 0.51 (0.30–0.91) 17/45 (37.8) 0/9 (0.0) 37.8 (5.3–52.4)a –
5–14
years
71/153 (46.4) 20/83 (24.1) 22.3 (10.0–33.5) 0.52 (0.34–0.77) 18/111 (16.2) 11/78 (14.1) 2.1 (8.9–12.1) 0.91 (0.43–1.67)
15–29
years
23/81 (28.4) 4/24 (16.7) 11.7 (10.0–26.3) 0.59 (0.23–1.43) 15/53 (28.3)b 0/5 (0.0) 28.3 (16.4–41.6) –
30+
years
33/146 (22.6) 7/69 (10.1) 12.4 (1.3–21.5) 0.45 (0.21–1.0) 27/116 (23.28) 1/34 (3.0) 20.3c (7.6–29.1) 0.13 (0.02–0.91)
BB, benzyl benzoate group; IVM, ivermectin group.
aPermethrin was used in <2 year olds; however, no significant difference was found.
bPermethrin was used in two pregnant women with no scabies at start, no follow-up visit.
cPermethrin was used in three cases with a history of neurological disease, two had scabies at start, none of the three at
follow-up.
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medical care related to adverse events, and community-
wide no hospitalizations or deaths occurred during the
study period. Mean age in those who reported adverse
events was not significantly different between the two
villages, 26 years in both groups. No side effects in the
IVM group occurred in children under the age of
10 years. In the BB group, 38 of 192 (19.8%, 95% CI
14.4–26.1) experienced worsening of their itch after treat-
ment, compared to four of 111 (3.6%, 95% CI 1.0–9.0)
in the IVM group.
Discussion
This is the first comparative study of MDA for scabies in
a general population setting and sets a precedent for pos-
sibly conducting general community MDA.
Our study showed that MDA for scabies using either
topical or oral medication reduced scabies prevalence by
a factor of up to 60%. Although the relative reduction in
risk was higher for MDA of IVM (60%), compared to
benzyl benzoate (48%), the difference was not statistically
significant. Both strategies had a low rate of adverse
events, but IVM was better tolerated, particularly in
terms of stinging and burning. The high scabies preva-
lence at baseline in the BB group of 38%, and IVM of
24% with frequent secondary bacterial infection, as has
been described in other studies, indicates that scabies is a
major health issue in Fiji.6,18
Scabies was found to be a major public health problem
in our two examined Fijian villages, with particularly
high rates among children in both villages. In our study,
69% of all children examined under the age of 5 years
had scabies in Tailevu, compared to 43% in Rewa. Sub-
sequently, scabies prevalence rates of 18% in schoolchil-
dren and 14% in infants were reported in Fiji (in 2006/
2007).6 The infection rates found in our study in Fiji
were much higher than in other community-based studies
in Brazil, Timor-Leste, the Solomon Islands, Vanuatu,
and Kenya.19–23 A study conducted in Papua, New
Guinea, found higher scabies prevalence than in our study
overall (87% in one village and 52% in another); how-
ever, numbers of examined people in this study were
low.24
Several previous non-comparative studies have shown a
marked reduction in scabies prevalence following MDA.
These include an MDA of topical permethrin in the San
Blas islands of the Republic of Panama25 and an MDA of
IVM on five isolated islands in the Solomon Islands.21 In
these studies, the prevalence of scabies fell from 33 to
25%, respectively, to <1% at three years. However, both
studies employed regular follow-up and retreatment to
maintain the sustained reduction in prevalence. Whether
the reduction seen in this study could be maintained
beyond one month without regular follow-up and re-
treatment is not known. Our study is the first compara-
tive study of MDA for scabies at the community level for
all ages. A previous comparative trial conducted in a
closed population of 84 children living in an urban hostel
of Delhi found that MDA IVM (two doses) was more
effective than individual treatment with permethrin (sin-
gle application) for symptomatic patients. In the first
six months of the study, permethrin was used, and there
were 22 cases, while after MDA IVM, there was only one
case of scabies detected in the subsequent six months.12
MDA has been documented as being effective for treat-
ing endemic scabies in the institutional setting for both
children and adults but has never been tested in a com-
parative study in a general population previously.7,10,11
Our findings provide support for an MDA treatment
approach rather than an individual-based approach for
communities with a high prevalence of scabies, similar to
that used in institutional settings.
There are, however, several limitations to our study.
The first is that follow-up was conducted only at
24–28 days after the initial administration of treatment
due to operational constraints, and therefore the longer-
term impact of MDA on scabies could not be assessed.
There were also considerable differences in participa-
tion rates between the two groups; 76% in the BB group
and 49% in the IVM group. This may have diminished
the apparent effect of the IVM MDA because of a
higher risk of reinfestation by non-treated community
members in this arm, as those treated may have been
exposed to untreated non-participants in their commu-
nity and hence have had a higher rate of reinfestation.
The reasons for the differences in participation may be
due to the BB group village being more isolated and that
scabies was identified very strongly by this community
as a serious and significant health issue (K. Haar, per-
sonal communication). Further, there was a high loss to
follow-up in this study, 54% in one group and 61% in
the other. This may have been because people that
were successfully treated did not return for follow-up
(K. Haar, personal communication), and particularly
those with persisting skin conditions such as tinea, boils,
and sores returned. This factor would have underesti-
mated the efficacy of MDA in both arms of the study.
Follow-up was particularly low in working-age people,
with only 9% of participants aged 15–29 years attending
in the IVM group. The relatively high follow-up rate of
70% among children aged 5–14 years in the IVM group
can be attributed to the research team visiting the school
to examine trial participants there. Insufficient communi-
cation with the village health workers of the importance
of all study participants returning for the second village
visit, regardless of their outcome, may have contributed
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to the poor follow-up rates. To improve community-
based studies and to enhance participation and follow-
up rates, timely planning and detailed written informa-
tion with precise dates, locations, and instructions
should be provided to all community leaders and partici-
pants.
Another confounder to our study was that the villages
were not equal in terms of access to water supply and to
primary healthcare. The BB group had a communal water
source useable only during the day and single dirt road
access, which was sometimes impassable during the wet
season. In the IVM group, continuous water supply and
plumbing to individual residences was common, with tar
road village access, and they were located closer to the
local community hospital. Although this situation has
improved in the intervening years, assessment of these
factors in future studies may determine their role.
One limitation of the study is that it was not truly
randomized; however, allocation to treatment was
decided by administrative chance, based on the avail-
ability of medication at start point. In any future
study, we would recommend that true randomization is
undertaken.
The protocol of applying benzyl benzoate for three
consecutive nights was the Fiji Ministry of Health Guide-
lines for the treatment of scabies at that time. One poten-
tial source of bias could be the correct application, which
we tried to rule out through specific questions post-
treatment. However, we did not control the application
per se, nor collect empty bottles. Permethrin was unavail-
able through the Government healthcare system at the
time of the study. Although this protocol allowed IVM to
be compared with the standard of care at that time, per-
methrin cream subsequently became the standard of care
and therefore for any future study should include per-
methrin cream. Ongoing studies in Fiji indicate that the
overall prevalence of scabies in the country has not chan-
ged since this study was performed (L. Romani, personal
communication), suggesting that the introduction of per-
methrin cream for individual case management has had
little impact on disease burden. Therefore, further investi-
gation into population-based control methods are as
pressing today as they were when this study was under-
taken in 2004.
Our study provides proof of principle that MDA for
scabies can reduce scabies prevalence at the community
level. A larger study is needed that has longer and
more complete follow-up, which includes a cost-effec-
tiveness analysis and compares MDA to the more con-
ventional approach of treating symptomatic cases and
their contacts. Without these data, scabies will continue
to be an endemic problem in many tropical developing
countries.
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